Combo Product Legislation Could Ride On User Fee Reauthorization If Not Passed In Lame Duck

A senior Johnson & Johnson official expressed skepticism the 21 st Century Cures Act as well as pending legislation addressing FDA's oversight of combination products will see movement in the lame-duck session due to unresolved funding issues, and he and a former counsel on the Senate health committee predicted a slew of FDA-related bills could be attached to user fee reauthorization legislation next year if Cures stalls in the lame duck. Legislation aimed at streamlining FDA's reviews of combination products,...